Abstract-Thyroid hormone has been reported to have significant effects on the peripheral vascular system, including relaxation of vascular smooth muscle cells and antiatherosclerotic effects. To exert its biological activity, thyroxine, which is a major secretory product of thyroid gland, needs to be converted to 3,5,3Ј-triiodothyronine (T 3 ) by iodothyronine deiodinase. Type I iodothyronine deiodinase (DI) is widely distributed and maintains circulating T 3 level, whereas type II iodothyronine deiodinase (DII) is present in a limited number of tissues to provide local intracellular T 3 . In the present study, we have identified iodothyronine deiodinase in cultured human coronary artery smooth muscle cells (hCASMCs) and human aortic smooth muscle cells (hASMCs). All of the characteristics of the deiodinating activity in hCASMCs and hASMCs were compatible with DII. Northern analysis demonstrated that DII mRNA was expressed in both hCASMCs and hASMCs, and DII mRNA levels as well as DII activities were rapidly increased by dibutyryl-cAMP or forskolin. These data demonstrate, for the first time, the expression of DII in human vascular smooth muscle cells, which is regulated by a cAMP-mediated mechanism. The present results suggest a previously unrecognized role of local T 3 production by DII in the pathophysiology of human vascular smooth muscle cells. Key Words: coronary artery smooth muscle Ⅲ aortic smooth muscle Ⅲ thyroid hormone receptor Ⅲ cAMP T hyroid hormone has profound effects on the peripheral vascular system. It is known as a vasodilator that acts directly on vascular smooth muscle cells (SMCs) to cause a relaxation of coronary arteries. 1,2 Hypothyroidism is known to be a risk factor for atherosclerosis, and thyroid hormone replacement in hypothyroidism has been reported to protect from atherosclerosis. 3, 4 To exert its biological activity, thyroxine (T 4 ), which is a major secretory product of the thyroid gland, needs to be converted to 3,5,3Ј-triiodothyronine (T 3 ) by iodothyronine deiodinase. 5, 6 There are two types, type I iodothyronine deiodinase (DI) and type II iodothyronine deiodinase (DII), which catalyze conversion of T 4 to T 3 . DI is present in thyroid gland, liver, kidney, and many other tissues, whereas DII is present in a limited number of tissues, including central nervous system, anterior pituitary tissue, and brown fat in the rat. 5,6 K m of DII is Ϸ2 nmol/L for T 4 , which is a hundred times lower than that of DI. DI activity is known to decrease in the hypothyroid state and is believed to have a primary role in maintaining circulating T 3 levels. DII activity, in contrast, increases in the hypothyroid state and is considered to play a critical role in providing local T 3 to regulate intracellular T 3 concentration. 5, 6 Although the source of T 3 mainly depends on circulating T 3 in most tissues, local intracellular conversion of T 4 to T 3 is an important source of T 3 in certain tissues where DII exists. 5, 6 A cDNA encoding DII was cloned from Rana catesbeiana tissues, 7 and its mammalian counterpart was subsequently isolated from rat brown fat. 8 In human, DII mRNA was unexpectedly detected in thyroid gland and other tissues, suggesting previously unrecognized roles of DII in those tissues. 9, 10 Considering that not only T 3 , but also T 4 has been reported to have effects on peripheral vascular function, 11-13 DII may exist in vascular SMCs and may contribute to the pathophysiology of human vascular systems by providing intracellular T 3 .
T hyroid hormone has profound effects on the peripheral vascular system. It is known as a vasodilator that acts directly on vascular smooth muscle cells (SMCs) to cause a relaxation of coronary arteries. 1, 2 Hypothyroidism is known to be a risk factor for atherosclerosis, and thyroid hormone replacement in hypothyroidism has been reported to protect from atherosclerosis. 3, 4 To exert its biological activity, thyroxine (T 4 ), which is a major secretory product of the thyroid gland, needs to be converted to 3,5,3Ј-triiodothyronine (T 3 ) by iodothyronine deiodinase. 5, 6 There are two types, type I iodothyronine deiodinase (DI) and type II iodothyronine deiodinase (DII), which catalyze conversion of T 4 to T 3 . DI is present in thyroid gland, liver, kidney, and many other tissues, whereas DII is present in a limited number of tissues, including central nervous system, anterior pituitary tissue, and brown fat in the rat. 5, 6 K m of DII is Ϸ2 nmol/L for T 4 , which is a hundred times lower than that of DI. DI activity is known to decrease in the hypothyroid state and is believed to have a primary role in maintaining circulating T 3 levels. DII activity, in contrast, increases in the hypothyroid state and is considered to play a critical role in providing local T 3 to regulate intracellular T 3 concentration. 5, 6 Although the source of T 3 mainly depends on circulating T 3 in most tissues, local intracellular conversion of T 4 to T 3 is an important source of T 3 in certain tissues where DII exists. 5, 6 A cDNA encoding DII was cloned from Rana catesbeiana tissues, 7 and its mammalian counterpart was subsequently isolated from rat brown fat. 8 In human, DII mRNA was unexpectedly detected in thyroid gland and other tissues, suggesting previously unrecognized roles of DII in those tissues. 9, 10 Considering that not only T 3 , but also T 4 has been reported to have effects on peripheral vascular function, [11] [12] [13] DII may exist in vascular SMCs and may contribute to the pathophysiology of human vascular systems by providing intracellular T 3 .
In the present study, we have characterized iodothyronine deiodinating activity and identified DII expression in cultured human coronary artery SMCs (hCASMCs) and human aortic SMCs (hASMCs). Cell Culture hCASMCs were obtained from Clonetics, and hASMCs were from Cascade Biologics. Both cells were demonstrated to express ␣-smooth muscle actin isoform but not factor VIII, indicating the nature of vascular SMCs. These cells were inoculated to 6-well plastic culture plates for the measurement of deiodinase activity or to 60-mm plastic culture dishes for Northern analysis, and the cells were cultured in modified MCDB 131 medium (HuMedia-SG2, KURABO, Osaka, Japan) as previously described. 14 After the cells became confluent, the medium was displaced with serum-free medium to arrest the proliferation of cells for 48 hours. The cells were then incubated in the medium containing compounds to be tested for indicated hours.
Materials and Methods

Materials
Measurement of Deiodinase Activity
Iodothyronine deiodinase activity was measured as previously described 15 with minor modifications. 16 Briefly, SMCs per each well (Ϸ2.0ϫ10 6 cells per well) were washed twice with the washing buffer (100 mmol/L potassium phosphate, pH 7.0), scraped off, and transferred into 1000 L of ice-cold buffer (100 mmol/L potassium phosphate, pH 7.0, containing 20 mmol/L DTT). After centrifugation at 3000 rpm for 15 minutes at 4°C, the supernatant was discarded. I was separated by column chromatography using AG 50W-X2 resin as previously described 16 and counted. The protein concentration was determined by the Bradford method using BSA as a standard. 17 The deiodinating activity was calculated either as percentage I Ϫ released or as femtomoles of I Ϫ released/mg protein per hour. After the characterization of deiodinase activity, the deiodinating activity was measured in duplicate by I Ϫ release from 2 nmol/L [ 125 I]T 4 in the presence of 1 mmol/L PTU at 37°C for 1 hour.
Northern Analysis and Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Northern analysis and RT-PCR were performed as previously described. 14, 18, 19 Total RNA was isolated from each dish, thyroid tissue, which was obtained from a patient with Graves' disease, and cerebral cortical tissue, which was obtained from an autopsy case. In Northern analysis, mRNA levels were quantified by densitometry, and the optical density of the DII band was corrected for GAPDH. RNA samples for comparison were analyzed on the same blot, and each experiment was performed at least twice with basically identical results.
Statistics
All values are expressed as meanϮSE. Statistical differences were evaluated by Student t test.
Results
Characteristics of Iodothyronine Deiodinase in hCASMCs and hASMCs
The deiodinating activity in hCASMCs was measured by the release of I Ϫ released/mg protein per hour in hCASMCs, as shown in Figure 1C . V max for rT 3 in hCASMCs was lower than that for T 4 (Table) . In hASMCs, kinetic constants for T 4 and rT 3 were comparable with those in hCASMCs (Table) . When we fractionated the hCASMC preparation, 9 the highest deiodinating activity was observed in microsomal fraction (755.4 versus 295.3 [total cell homogenate] fmol I Ϫ released/mg protein per hour). Taken together, these results indicate that the characteristics of the deiodinating activity in hCASMCs and hASMCs are compatible with DII.
Identification of DII mRNA in Cultured hCASMCs and hASMCs
Northern analysis using human DII cRNA probe was performed to examine whether DII mRNA is expressed in human vascular SMCs. As shown in Figure 2 , hybridization signals of DII mRNA Ϸ7.5 kb in size were clearly demonstrated in hCASMCs and hASMCs. The size of DII mRNA in hCASMCs and hASMCs was indistinguishable from that in human thyroid gland, 9 although the amount of DII mRNA in hCASMCs or hASMCs was less than that in human thyroid gland. These results indicate that DII mRNA is expressed in both hCASMCs and hASMCs.
Regulation of DII Expression in Cultured hCASMCs and hASMCs by Thyroid Hormones
One of the important characteristics of DII is the negative regulation of its activity by thyroid hormones. 5, 6 To study the effects of thyroid hormones on deiodinating activity in human vascular SMCs, thyroid hormones were added to the culture medium for 6 hours before the harvest of cultured SMCs. As shown in Figure 3A , the deiodinating activity was decreased by thyroid hormones, and the potency of the inhibitory effect was T 4 ϾrT 3 ϾT 3 in hCASMCs. Although the deiodinating activity was measured by the release of I Ϫ from [ 125 I]T 4 , control studies demonstrated that the effects of T 4 or rT 3 on the deiodinating activity were time dependent and are thus not explained by dilution of the substrate with T 4 or rT 3 carried over into the assay of deiodinase activity. More importantly, 10 Ϫ7 mol/L rT 3 added to the assay buffer of deiodinase activity did not affect the release of I Ϫ from [ 125 I]T 4 . DII mRNA in hCASMCs was inhibited by thyroid hormones; the potency of the inhibitory effect was T 3 ϾT 4 ϾrT 3 , as shown in Figure 3B . Basically identical inhibitory effects of thyroid hormones on the deiodinating activity and DII mRNA expression were observed in hASMCs. Inhibition of the deiodinating activity in hCASMCs and hASMCs by thyroid hormones further indicates the presence of authentic DII activity in cultured hCASMCs and hASMCs. These results suggest that T 3 suppresses DII activity mainly at the pretranslational level, whereas T 4 or rT 3 suppresses DII activity largely at the post-translational level in hCASMCs and hASMCs, in agreement with previous observations for DII in other tissues and cells. 14,20 -22
Stimulation of DII Expression in Cultured hCASMCs and hASMCs by Forskolin or Dibutyryl cAMP ([Bu] 2 cAMP)
Because DII activity has been known to be regulated by a cAMP-dependent mechanism, 5,6 the effects of cAMPelevating agents on DII expression in human vascular SMCs were studied. As shown in Figures 4A and 4B , DII activity and DII mRNA in cultured hCASMCs were clearly increased Effects of thyroid hormones on DII activity and DII mRNA in hCASMCs. A, DII activity in hCASMCs incubated with serum-free medium only (control) or serum-free medium with thyroid hormones for 6 hours. DII activity was measured as described in Materials and Methods. DII activity shown represents meanϮSE of 3 wells in one experiment. *PϽ0.05 compared with control. B, DII mRNA (DII mRNA/GAPDH mRNA ratio) in hCASMCs incubated with serum-free medium only (control) or serum-free medium with thyroid hormones for 6 hours. Optical density of the DII band was corrected for GAPDH, and results are expressed as a percentage of the value obtained for control. by treatment with forskolin (10 Ϫ5 mol/L) or (Bu) 2 cAMP (10 Ϫ3 mol/L) for 6 hours. In the time-course study, both DII activity and DII mRNA in cultured hCASMCs were increased by forskolin within 3 hours, as shown in Figure 5 . When actinomycin D (5 g/mL) was added to the culture medium 30 minutes before the incubation with forskolin (10 Ϫ5 mol/L) for 6 hours, the stimulation of DII activity was completely abolished, indicating the requirement of mRNA synthesis for the stimulation of DII activity by a cAMP-mediated mechanism. Forskolin stimulated DII activity and DII mRNA in hASMCs in the same manner, as shown in Figure 6 .
Identification of Thyroid Hormone Receptor (TR) Isoforms in Cultured hCASMCs and hASMCs by RT-PCR
To investigate whether TRs are expressed in hCASMCs and hASMCs, we have performed RT-PCR analyses of TR isoforms in those cells. In control human cerebral cortical tissue, all of the TR isoforms were clearly demonstrated by RT-PCR, as shown in Figure 7 . Although all of the TR isoforms were also detected in both hCASMCs and hASMCs by RT-PCR, strong expression of mRNA for TR␣1 and TR␣2 isoforms and relatively weak expression of mRNA for TR␤1 and TR␤2 were observed in both hCASMCs and hASMCs, as shown in Figure 7 .
Discussion
The present results have clearly demonstrated that iodothyronine deiodinating activities are present in cultured hCASMCs and hASMCs. The deiodinating activities in hCASMCs and hASMCs were dependent on the protein concentrations, incubation period, pH, temperature, and substrate concentrations. These characteristics clearly indicate the enzymatic nature of the deiodinating activities. The deiodinating activities in hCASMCs and hASMCs were not inhibited by 1 mmol/L PTU and were demonstrated to have low K m for T 4 and rT 3 . Furthermore, the deiodinating activities were decreased by the addition of thyroid hormones to the culture medium. Iodothyronine deiodinating activities in hCASMCs and hASMCs, therefore, have characteristics compatible with DII. Northern analysis using human DII cRNA probe clearly demonstrated the hybridization signals with Ϸ7.5 kb in size in hCASMCs and hASMCs. The size of DII mRNA in hCASMCs and hASMCs was indistinguishable from that in human thyroid gland. 9 The expression of DII in both hCASMCs and hASMCs suggests the ubiquitous expression of DII in human vascular SMCs. Although the expression of DII mRNA in human heart and skeletal muscle has been observed after the molecular cloning of human DII cDNA, 10 the present results appear as the first demonstration of the expression of DII in human vascular SMCs. DII activity is controlled by thyroid hormones at two levels. T 4 and rT 3 suppress DII activity mainly at the post-translational level through acceleration of the degradation rate of DII protein. 20 Both T 4 and rT 3 are more potent in producing this effect than T 3 , suggesting that this effect does not require TRs. Recently, proteasomal degradation has been demonstrated to be involved in the post-translational regulation of DII activity by thyroid hormones. 23 In contrast, T 3 suppresses DII activity by decreasing DII mRNA without affecting its half-life, indicating that this effect is due to suppression of transcription of DII gene through TRs. 21 Because the half-life of DII mRNA is 2 hours and that of DII enzyme is 40 minutes, the suppression of DII by thyroid hormones is very rapid whether the decrease in activity is induced by transcriptional or post-translational effects. 21 In the present study, thyroid hormones inhibited DII mRNA expression, and the potency of the inhibitory effect was T 3 ϾT 4 ϾrT 3 . Although the deiodinating activity was also decreased by thyroid hormones, the potency of the inhibitory effect was T 4 ϾrT 3 ϾT 3 . These results suggest that T 3 sup- Figure 7 . RT-PCR of TR isoforms in hCASMCs, hASMCs, and human cerebral cortical tissue. Total RNA was isolated from hCASMCs, hASMCs, and human cerebral cortical tissue obtained at autopsy. After treatment with DNase I (Life Technologies), RT-PCR was performed on 1 g of total RNA using AmpliTaq Gold (Roche Molecular Systems, Inc) as previously described 18 with minor modifications. For PCR, the synthesized sense and antisense primers for human TR isoforms 19 were the following: TR␣1, 5Ј, 1659-AAGATGCCCTCAACTCACC-1677, and 3Ј, 1870-TCTTCATTTGTCTTCTCCCC-1851; TR␣2, 5Ј, 1653-ATCCCGTAAGACCTCCTTCC-1672, and 3Ј, 1919-AAACA-GACTCATGCCCGAC-1901; TR␤1, 5Ј, 550-GAGGAGAAGAAA-TGTAAAGG-569, and 3Ј, 717-GGAATAGGATGGATGGAG-700; and TR␤2, 5Ј, 41-GGGCTGGAGAATGCATGCGTAGACT-65 and 3Ј, 279-ATTCACTGCCCAGGCCTGTTCCATA-255. Reaction products were analyzed by 2% agarose gel electrophoresis, and resulting bands were visualized by SYBR Green (Molecular Probes). Total RNA that was treated in an identical manner except for the substitution of water for reverse transcriptase showed no bands in RT-PCR for each TR isoform. presses DII activity mainly at the pretranslational level, whereasT 4 or rT 3 suppresses DII activity largely at the post-translational level in hCASMCs and hASMCs, in agreement with previous observations for DII in other tissues and cells. 14,20 -22 The possible transcriptional regulation of DII by T 3 is further supported by the presence of TR isoforms in hCASMCs and hASMCs demonstrated in the present study. Because DII expression in hCASMCs and hASMCs could be increased in the hypothyroid state, DII in human vascular SMCs might play a role in the protection of human vessels from local T 3 deficiency in hypothyroidism.
In the present study, both DII activities and DII mRNA levels were rapidly stimulated by forskolin or (Bu) 2 cAMP in hCASMCs and hASMCs, suggesting the pretranslational regulation of DII expression by a cAMP-dependent mechanism. The rapid stimulation of DII mRNA and DII activity was also observed in human skeletal muscle cells, rat astrocytes, and pineal gland. 14, 24, 25 Recently, a functional cAMP response element has been reported to be present in the human DII promoter region. 26 Taken together, it is suggested that DII expression in hCASMCs and hASMCs is regulated by a cAMP-dependent mechanism at the transcriptional level.
It is generally accepted that calcium-dependent phosphorylation of myosin light chains initiates the contraction of vascular smooth muscle. 27 Although the precise mechanisms underlying the action of endogenous vasodilator remain to be identified, it is postulated that cAMP-dependent protein kinase A inhibits calcium-dependent myosin light chain kinase. 27, 28 In the present study, it was demonstrated that intracellular accumulation of cAMP significantly stimulated DII expression in hCASMCs and hASMCs. Given that thyroid hormones have been reported to relax vascular SMCs directly, 1,2 local production of T 3 by DII might be another vasodilative mechanism mediated by cAMP regulatory cascade.
It has been reported that low serum selenium concentration increases the risk of ischemic heart disease. 29 However, the mechanisms involved in the increased frequency of coronary heart disease in selenium deficiency are not known. Human DII cDNA contains in-frame TGA triplets that are not for termination codons but for the rare amino acid selenocysteine, which contains selenium. 8, 10 Because selenium is required to exert the full DII activity, 24 one might speculate that local T 3 production by DII in human vascular SMCs could be decreased by low serum selenium, which may be related to the increased risk of ischemic heart disease in selenium deficiency. Further studies are required to elucidate the pathophysiological roles of DII and selenium deficiency in atherosclerosis.
The physiological importance of intracellular thyroid hormone activation by DII has been clearly demonstrated in certain tissues. Adenohypophyseal T 3 production by DII plays a role in feedback regulation of thyrotropin secretion by thyroid hormones. 5, 6 In the rat brown adipose tissue, the expression of uncoupling protein is regulated by locally generated T 3 , which is provided by DII. 30 In the present study, TRs were demonstrated in hCASMCs and hASMCs by RT-PCR, suggesting that locally produced T 3 by DII might play a role through TRs in vascular SMCs. Although the target genes induced by thyroid hormones in vascular SMCs are not known, it is of interest to study the possible role of locally produced T 3 by DII in the regulation of vascular SMC-specific gene expression, which may be associated with SMC dedifferentiation that relates to atherosclerosis and ischemic heart disease. 31, 32 In summary, the present results demonstrate the expression of functional DII in human vascular SMCs, which may open novel perspectives on the roles of thyroid hormone metabolism in the pathophysiology of human vascular SMCs.
